胶质母细胞瘤切除中脑室开放对患者结局的影响
回顾性分析2013—2018年单中心200例新诊断及复发幕上胶质母细胞瘤(GBM)切除患者,26.5%发生脑室开放(VE)。VE与术后脑积水、分流、假性脊膜膨出、硬膜下血肿及柔脑膜播散、远处复发均无显著差异;存在室管膜下病变者生存更差,但VE未改变接触脑室肿瘤患者的生存。
要点
- VE未增加术后并发症、柔脑膜播散或远处复发
- 术前存在室管膜下病变者生存更差,VE未进一步影响生存
- 为最大化切除范围,GBM切除中可接受脑室开放
核心结论
- GBM切除中脑室开放(VE)与不良患者结局无关,术者可利用VE提高切除程度。
研究设计与样本
- 单中心回顾性队列,检索加州大学旧金山分校肿瘤登记库,纳入2013—2018年由资深术者手术的新诊断及复发幕上GBM患者,共200例;采用术前术后影像评估肿瘤与室管膜下区(SVZ)关系、大小及切除程度,术后影像和/或手术记录判定VE;证据等级class II。
主要发现
- 26.5%患者切除中发生VE;VE组更常见术前室管膜下病变(41.5% vs 15.0%,p < 0.001)。
- VE组与非VE组术后脑积水(1.9% vs 4.8%,p = 0.36)、脑室腹腔分流(0% vs 3.4%,p = 0.17)、假性脊膜膨出(7.5% vs 5.4%,p = 0.58)、硬膜下血肿(11.3% vs 3.4%,p = 0.07)无差异。
- 后续柔脑膜病变(7.5% vs 10.2%,p = 0.57)与远处脑实质复发(17.0% vs 23.1%,p = 0.35)在两组间无差异。
- 新诊断患者中肿瘤接触SVZ(I或II型)者生存劣于未接触者(1.27 vs 1.84年,p = 0.014,HR 1.8,95% CI 1.08-3.03)。
- 在高风险SVZ I和II型肿瘤患者中,VE与生存无关(1.15 vs 1.68年,p = 0.151,HR 0.59,95% CI 0.26-1.34)。
临床怎么用
- GBM切除中如为提高切除程度需进入脑室,不必因担心播散或生存受损而回避VE。
- 对术前存在室管膜下病变者应关注其较差预后,但VE本身不构成额外生存风险。
局限性
- 单中心、单术者回顾性队列,VE由术后影像和/或手术记录判定,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tumor proximity to the ventricle and ventricular entry (VE) during surgery have both been associated with worse prognoses; however, the interaction between these two factors is poorly understood. Given the benefit of maximal tumor resection, it is imperative for surgical planning and technique to know if VE has negative consequences for patient survival and tumor dissemination. METHODS: The University of California, San Francisco tumor registry was searched for patients with newly diagnosed and recurrent supratentorial glioblastoma (GBM) who underwent resection by the senior author between 2013 and 2018. Tumor location with respect to the subventricular zone (SVZ), size, and extent of resection were assessed using pre- and postoperative imaging. VE was determined by postoperative imaging and/or the operative report. RESULTS: In this 200-patient cohort of newly diagnosed and recurrent GBM, 26.5% of patients had VE during resection. Patients with VE were more likely to have preexisting subependymal disease (41.5% vs 15.0%, p < 0.001). Comparing patients with VE to those without VE, there was no difference in the rates of postoperative hydrocephalus (1.9% vs 4.8%, p = 0.36), ventriculoperitoneal shunting (0% vs 3.4%, p = 0.17), pseudomeningoceles (7.5% vs 5.4%, p = 0.58), or subdural hematomas (11.3% vs 3.4%, p = 0.07). Importantly, rates of subsequent leptomeningeal disease (7.5% vs 10.2%, p = 0.57) and distant parenchymal recurrence (17.0% vs 23.1%, p = 0.35) were not different between the groups. Newly diagnosed patients with tumors contacting the SVZ (type I or II) had worse survival than patients with tumors that did not contact the SVZ (type III or IV) (1.27 vs 1.84 years, p = 0.014, HR 1.8, 95% CI 1.08-3.03), but VE was not associated with worse survival in these patients with high-risk SVZ type I and II tumors (1.15 vs 1.68 years, p = 0.151, HR 0.59, 95% CI 0.26-1.34). CONCLUSIONS: VE was well tolerated, with postoperative complications being rare events. There was no increase in leptomeningeal spread or distant parenchymal recurrence in patients with VE. Finally, although survival was worse for patients with preoperative subependymal disease, VE did not change survival for patients with tumors contacting the ventricle. Therefore, VE during GBM resection is not associated with adverse patient outcomes and should be used by surgeons to enhance extent of resection.■ CLASSIFICATION OF EVIDENCE Type of question: therapeutic; study design: retrospective cohort; evidence: class II.
引用
- Young JS, Gogos AJ, Pereira MP, et al. Effects of ventricular entry on patient outcome during glioblastoma resection. J Neurosurg. 2021. PMID: 33418530. doi:10.3171/2020.7.JNS201362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。